Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a clinical stage biotech company focused on developing treatments for endocrine and metabolic disorders using its Precision Endocrine Peptide (PEP) platform. The company's main product candidate, canvuparatide, has shown promising data in Phase 2 trials for hypoparathyroidism (HP) and has the potential for differentiation in convenience, safety, and efficacy compared to other therapies. With a strong pipeline and a healthy cash runway, we believe that MBX has significant potential for success and we maintain our Buy rating.

Bears say

MBX Biosciences is facing potential degradation in efficacy for its pipeline drugs, specifically canvuparatide, due to variations in peak and trough with weekly dosing according to various KOL perspectives, leading to only moderate response rates and potentially making it a less preferred option compared to Yorvipath. This, combined with our calculated risk-adjusted discounted cash flow analysis, leads to our negative outlook on the company's stock as we see limited potential for significant revenues in the long term, with our projected peak revenues for their pipeline drugs at around $2.2B.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.